Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The first case of COVID-19 treated with the complement C3 inhibitor AMY-101

Clinical Immunology(2020)10.1016/j.clim.2020.108450Source: DataRank Database

The first case of COVID-19 treated with the complement C3 inhibitor AMY-101 is a research paper published in Clinical Immunology (2020). On theSindex it has a DataRank of 0. It has been cited 297 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access297 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)OA: greenTopics (19)Linked Datasets (20)DataCite Reuse (20)IDs (PubMed, PMC)Annotations (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (12)

Annalisa Ruggeri ORCID,Antonio M. Risitano ORCID,Piera Angelillo,Despina Yancopoulou,Dimitrios C. Mastellos ORCID

Live enrichment

PubMed:32360516 PMC:PMC7189192

US National Institutes of Health

Grant: AI068730

NIAID NIH HHS

Grant: P01 AI068730

US National Institutes of Health

Grant: DFG SFB1149 A01

Alexion

Alnylam and Rapharma

Dolce&Gabbana Fashion Firm

Novartis

Institutional National 5x1000 Grant

greenLicense: https://www.elsevier.com/legal/tdmrep-license

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7189192

publisherhttps://api.elsevier.com/content/article/PII:S1521661620303314?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1521661620303314?httpAccept=text/plain

Europe_PMChttps://europepmc.org/articles/PMC7189192

Europe_PMChttps://europepmc.org/articles/PMC7189192?pdf=render

MeSH Terms

LungHumansPneumonia, ViralCoronavirus InfectionsAtrial FibrillationHypertensionHypercholesterolemiaPeptides, CyclicAntiviral AgentsTreatment OutcomeComplement ActivationAgedComplement C3MaleComplement Inactivating AgentsPandemicsBetacoronavirusCOVID-19SARS-CoV-2

Additional file 1 of Natural products provide a new perspective for anti-complement treatment of severe COVID-19: a review

10.6084/m9.figshare.15071437.v1figshare

Additional file 1 of Natural products provide a new perspective for anti-complement treatment of severe COVID-19: a review

10.6084/m9.figshare.15071437figshare

Additional file 1 of Inferring SARS-CoV-2 functional genomics from viral transcriptome with identification of potential antiviral drugs and therapeutic targets

10.6084/m9.figshare.16590735.v1figshare

Additional file 1 of Inferring SARS-CoV-2 functional genomics from viral transcriptome with identification of potential antiviral drugs and therapeutic targets

10.6084/m9.figshare.16590735figshare

Additional file 1 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462377.v1figshare

Additional file 1 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462377figshare

Additional file 2 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462380.v1figshare

Additional file 2 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462380figshare

Additional file 3 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462386.v1figshare

Additional file 3 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462386figshare

Additional file 4 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462389.v1figshare

Additional file 4 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462389figshare

Additional file 5 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462392.v1figshare

Additional file 5 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462392figshare

Additional file 6 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462395.v1figshare

Additional file 6 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462395figshare

Additional file 7 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462401.v1figshare

Additional file 7 of Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

10.6084/m9.figshare.20462401figshare

Additional file 2 of Inferring SARS-CoV-2 functional genomics from viral transcriptome with identification of potential antiviral drugs and therapeutic targets

10.6084/m9.figshare.16590741figshare

Additional file 2 of Inferring SARS-CoV-2 functional genomics from viral transcriptome with identification of potential antiviral drugs and therapeutic targets

10.6084/m9.figshare.16590741.v1figshare